Pharmaceutical Executive November 9, 2021
Julian Upton

Pharma organizations have long been vigilant in protecting their intellectual property and financial information, but the disruption of COVID-19 has seen an expansion of the ‘cyberattack surface.’

The pharma value chain has become increasingly digital and complex, with networks of remote and on-premises workers regularly accessing disparate data, clouds, and applications. In addition, pharma companies are increasingly customer-driven, with more data available through patient and healthcare provider portals. All of this, says Troy Ament, chief information security officer (CISO) for healthcare at Fortinet, makes pharma “a target for cybercriminals.”

The bioeconomy is one of the five key technologies in need of protection from cybercrime, according to the US National Counterintelligence and Security Center. “Companies in this space are targets because...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Cybersecurity, Health IT, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID, Technology
As Change reviews data impacted by cyberattack, here's what the notification process could look like
Healthcare security culture steadily improving, but gaps remain
CISA proposes rule for hospitals to disclose ransom payments
What Change Healthcare And The Postal Service Can Tell Us About The Coming Platform Revolution
UnitedHealth pays $3.3B to providers following Change hack

Share This Article